3 days Ago By ABMN Staff
BioNTech SE ( NASDAQ:BNTX – Free Report ) – Research analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of BioNTech in a report issued on Wednesday, November 13th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will earn ($3.
79) per share for the year, down from their previous estimate of ($1.84). The consensus estimate for BioNTech’s current full-year earnings is ($3.
68) per share. Leerink Partnrs also issued estimates for BioNTech’s Q4 2024 earnings at $0.42 EPS, Q1 2025 earnings at ($1.
81) EPS, Q2 2025 earnings at ($2.30) EPS, Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $1.
85 EPS, FY2025 earnings at ($0.07) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($2.
04) EPS and FY2028 earnings at ($1.09) EPS. BioNTech ( NASDAQ:BNTX – Get Free Report ) last released its quarterly earnings results on Monday, November 4th.
The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.
07. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.
08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.
16%. The firm’s revenue was up 38.9% compared to the same quarter last year.
During the same period last year, the business posted $0.73 earnings per share. Read Our Latest Research Report on BNTX BioNTech Stock Performance BNTX opened at $101.
87 on Monday. The firm’s 50-day moving average price is $113.57 and its 200-day moving average price is $97.
36. The company has a market cap of $24.42 billion, a P/E ratio of -48.
51 and a beta of 0.26. The company has a quick ratio of 7.
21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.
BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49.
Institutional Trading of BioNTech Hedge funds and other institutional investors have recently made changes to their positions in the company. Baillie Gifford & Co. lifted its stake in shares of BioNTech by 0.
4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares during the last quarter.
FMR LLC lifted its position in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after buying an additional 5,598,190 shares during the last quarter.
Capital World Investors lifted its position in BioNTech by 0.5% in the first quarter. Capital World Investors now owns 943,116 shares of the company’s stock valued at $87,002,000 after buying an additional 4,369 shares during the last quarter.
Deerfield Management Company L.P. Series C boosted its stake in BioNTech by 4.
3% during the second quarter. Deerfield Management Company L.P.
Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after buying an additional 24,426 shares during the period. Finally, Candriam S.C.
A. increased its position in shares of BioNTech by 261.2% during the second quarter.
Candriam S.C.A.
now owns 578,998 shares of the company’s stock valued at $46,526,000 after acquiring an additional 418,695 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.
BioNTech Company Profile ( Get Free Report ) BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. See Also Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.
com's FREE daily email newsletter ..
